logo
logo

Invetx Announces $15 Million Series A Financing and Industry-leading Partnerships for Animal Biopharmaceutical Development

Feb 24, 2020over 5 years ago

Amount Raised

$15 Million

Round Type

series a

Boston

Description

Invetx, a pioneering animal health biopharmaceutical company, today announced a $15 million Series A financing and founding collaborations with WuXi Biologics and AbCellera. The financing was led by Invetx’s founding investor, Anterra Capital, and will drive clinical entry of a first therapeutic candidate and preclinical development of Invetx’s broader pipeline of protein-based therapeutics. With this financing, the leading global biologics CDMO WuXi Biologics joins Invetx as an investor and a research collaborator.

Company Information

Company

Invetx

Location

Boston, Massachusetts, United States

About

Our team of R&D leaders from human biotech and animal health is building the premier biotechnology platform for protein-based therapeutics in animal health.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People